Alnylam’s full analysis of its clinical trial data for an experimental treatment known as givosiran — a drug candidate from the company that relies on a Nobel prize-winning gene-silencing technique — shows more promise for some patients than others.

The analysis, which the company presented Friday at the annual meeting of the European Association for the Study of the Liver (EASL), is a more complete version of the topline data that the company released in March and looks at patients with acute intermittent porphyria, a rare disease that can cause acute and sometimes life-threatening attacks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy